For Investors

The Next Frontier in
Precision Neuropsychiatry.

NeuroBiome is positioned at the intersection of AI, metagenomics, and clinical neuroscience — addressing a massive unmet need in one of medicine's largest markets.

Open investor questionnaire ↗
Market Opportunity

The Numbers Tell the Story

€120B+
Total Addressable Market (TAM)
Europe & North America
200M+
People living with neuropsychiatric
disorders in Europe & North America
Investment Thesis

Why NeuroBiome, Why Now

First-Mover Advantage

NeuroBiome is the first platform dedicated to integrating shotgun metagenomics, AI-driven microbiome modeling, and precision microbial adjuvant design to address neuropsychiatric disorders.

Technology

Our in-house AI platform and growing patient database create a defensible, data-driven moat that deepens with every patient interaction.

Large Addressable Market

NeuroBiome operates at the intersection of three rapidly expanding sectors: neuropsychiatric therapeutics, precision diagnostics, and microbiome-based medicine — each representing multi-billion-dollar global markets.

Scalable Platform Model

Our AI and bioinformatics infrastructure is inherently scalable. Every new patient enriches the dataset, strengthens predictive models, and reduces the marginal cost of delivering personalized insights.

Massive Unmet Clinical Need

Neurological and psychiatric disorders are among the leading causes of disability worldwide and have a profound impact on patients' quality of life. Despite this, many patients experience limited treatment response or significant side effects.

Microbiome-informed adjuvant medicine offers a new biological lever to enhance therapeutic precision and effectiveness.

Strong Scientific Foundation

NeuroBiome is built on a rapidly advancing body of peer-reviewed research linking the gut microbiome to brain function, drug metabolism, and treatment response. Our scientific approach is grounded in deep expertise in microbiome science and neuroactive metabolites.

Be a Game-Changer

The Opportunity

NeuroBiome is building a platform for microbiome-informed precision medicine in neuropsychiatric disorders, with the goal of improving treatment outcomes and helping address the global burden of brain health through more personalized and holistic care.

Strategic Roadmap

Path to Scale

Phase 1
2026
Foundation & Clinical Validation
Company formation, in-house development of the AI microbiome modeling platform, and initial clinical cohort validation.
Phase 2
2027
Clinical Expansion & Data Consolidation
Initial market entry, expansion of clinical cohorts, publication of peer-reviewed results, and validation of the clinical workflow through partnerships with clinicians and specialized centers.
Phase 3
2028
Regulatory Advancement & Market Positioning
Expansion within the Italian market and preparation for entry into additional EU markets, while strengthening regulatory positioning and clinical partnerships.
Phase 4
2029+
Scalable Platform Growth
European expansion, advanced AI automation, and the development of a strong recurring revenue base, positioning NeuroBiome as a leading platform in neuro-microbiome precision medicine.

We are seeking strategic partners and early-stage investors who share our conviction that the microbiome is the next major frontier in precision medicine.